Operating Margin

French flavor giant posts strong 2025 results despite currency woes, fueled by booming emerging markets and a deep commitment to natural, sustainable ingredients.

A new report says cutting streaming can get you a home in years. But does this advice ignore a broken housing market? We investigate the real path to a down payment.

Align Partners launches a major governance overhaul campaign at Dentium, aiming to fix the 'Korea discount' and unlock value at the undervalued market leader.

The French biopharma giant posts strong 2025 results and forecasts over 13% growth, fueled by a booming pipeline and unexpected market advantages.

Aviation services giant AAR brings back a key architect of its growth strategy as its new CFO, signaling a commitment to continuity and ambitious expansion.

As BJ’s prepares to report Q4 results, investors are watching if a pizza relaunch and new efficiencies can overcome industry-wide cost pressures.

Moody's affirms the Estonian energy giant's Baa3 rating, but a negative outlook signals deep-seated risks from its oil shale legacy and market volatility.

Bio-Techne promotes Steve Crouse to lead its high-growth Diagnostics and Spatial Biology unit, signaling a strategic focus on innovation after a key divestiture.

A surge in healthcare job applications offers a prime opportunity, but new data reveals a critical bottleneck preventing companies from turning interest into hires.

A new powerhouse partnership promises to reshape the US load handling market, expanding access to HIAB cranes and MOFFETT forklifts across key regions.

The asset manager starts 2026 with a bang, fueled by massive European inflows, a strategic shift to higher-fee products, and resilient digital asset growth.

With key leadership promotions, AscellaHealth aims to streamline the complex path from drug discovery to patient delivery for life sciences companies worldwide.

A Dutch-German gas project powered by offshore wind achieves a top methane certification, offering a new blueprint for Europe's energy transition.

With a 135% revenue surge and a key FDA submission for its kidney transplant drug, Hansa Biopharma is poised for a pivotal year of expansion.

A new report shows the carbon removal market has the tools to fight climate change, but widespread corporate inaction threatens to strand vital projects.

ARS Pharma's neffy challenges the EpiPen with new data on efficacy, cost-effectiveness, and patient preference, promising a less intimidating allergy emergency.

Cloud communications firm RingCentral will join the S&P SmallCap 600, triggering investment shifts and highlighting tech's growing market influence.

With its IPO complete, Cambridge Acquisition Corp. enters a disciplined SPAC market with a clear focus on wellness, hemp, and psychedelic tech targets.

Ambience Healthcare appoints Mike Valli as CRO/CVO, signaling a bold new strategy to prove AI's ROI by tackling clinician burnout and revenue leakage.

As it marks its 40th year, the legal finance giant's impressive 3.0x return on capital highlights the growing appeal of legal assets as a stable asset class.